Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF 121 (AdVEGF121) versus maximum medical treatment

Duncan J. Stewart,J D Hilton,J. M.O. Arnold,J Gregoire,A Rivard,Stephen L. Archer,F. Charbonneau,Eric A. Cohen,M. Curtis,Christopher E. Buller,Farrell O. Mendelsohn,Nabil Dib,P. Page,John Ducas,Sylvain Plante,J Sullivan,Jennifer Macko,Camilla Rasmussen,Paul D. Kessler,Henrik S. Rasmussen

Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF 121 (AdVEGF121) versus maximum medical treatment

2006

Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF 121 (AdVEGF121) versus maximum medical treatment

Keywords:

Vascular disease
Angiogenesis
Revascularization
Randomized controlled trial
Genetic enhancement
Angina
Physical therapy
Heart disease
Diabetes mellitus
Medicine
Canadian Cardiovascular Society
Cardiology
Internal medicine
Coronary artery disease
Surgery
Virology
Ischemia
Perfusion scanning

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

235

Citations